cystic fibrosis news from FierceBiotech
News
Inspire Pharma shares soar 75% on CF data
Shares of Durham, NC-based Inspire Pharmaceuticals took off this morning after researchers announced that a late-stage trial of its cystic fibrosis therapy produced promising results. Patients taking Read more...
Inimex raises $22M in VC
Despite a recent Ernst & Young report on the funding challenges in Canada, Inimex Read more...
Inspire abandons nasal spray after drug flunks trial
Disappointed by lackluster data, Inspire Pharmaceuticals has abandoned development of its epinastine nasal spray for the treatment of seasonal allergic rhinitis. Subjects treated with the nasal Read more...
Funds from non-profit groups flow to biotech R&D
Epix Pharmaceuticals said this morning that its development pact with the Cystic Fibrosis Foundation has mushroomed into a $50 million deal, adding $37.7 million to the $12 million already provided Read more...
ALSO NOTED: Pharmaxis reports Phase II CF data; New Zealand publishes biotech industry stats; and much more...
> Pharmaxis announced today that a Phase II clinical trial in children with cystic fibrosis demonstrated excellent lung function improvement following three months treatment with Bronchitol that Read more...
Developers seek alternatives to animal ingredients
The brouhaha over heparin has cast a spotlight on the use of animal products in therapies. It also Read more...
Transave aims for proof-of-concept after $35M round
Venture capitalists Rich Kollender and Steve Kraus are joining the board at Transave after helping come up with $35 million in new venture backing to get the developer through to proof-of-concept Read more...
Gilead, Parion partner on pulmonary disease
Parion Sciences has signed on Gilead to partner up on pulmonary disease therapies. Gilead will pay $5 million up front and $5 million in exchange for an equity stake in Parion for worldwide Read more...
Genaera abandons two studies in pipeline switch
Genaera has changed gears on its pipeline strategy after shuttering two mid-stage studies--one for Lomucin as a therapy for cystic fibrosis and the other for squalamine to treat prostate cancer. The Lomucin study was abandoned for "reasons of futility" while squalamine was shelved due to trouble restarting the cancer trial. Genaera will now focus on trodusquemine for obesity and the anti-IL-9 asthma program licensed to MedImmune.
"We continue to be very encouraged by the progress …
Read more...Get more cystic fibrosis coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends